2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease (Q38199478)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 March 2014

Language	Label	Description	Also known as
English	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease	scientific article published on 25 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease (English)

1 reference

Europe PubMed Central

30 August 2017

1 reference

based on heuristic

inferred from title

Peter Meldgaard

object named as

P Meldgaard

4

0 references

author name string

B Besse

1

1 reference

Europe PubMed Central

30 August 2017

P Baas

3

1 reference

Europe PubMed Central

30 August 2017

M Nicolson

5

1 reference

Europe PubMed Central

30 August 2017

L Paz-Ares

6

1 reference

Europe PubMed Central

30 August 2017

M Reck

7

1 reference

Europe PubMed Central

30 August 2017

E F Smit

8

1 reference

Europe PubMed Central

30 August 2017

K Syrigos

9

1 reference

Europe PubMed Central

30 August 2017

R Stahel

10

1 reference

Europe PubMed Central

30 August 2017

E Felip

11

1 reference

Europe PubMed Central

30 August 2017

S Peters

12

1 reference

Europe PubMed Central

30 August 2017

Panel Members

13

1 reference

Europe PubMed Central

30 August 2017

ESMO

14

1 reference

Europe PubMed Central

30 August 2017

A Adjei

2

1 reference

Europe PubMed Central

30 August 2017

publication date

25 March 2014

1 reference

Europe PubMed Central

30 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

30 August 2017

25

1 reference

Europe PubMed Central

30 August 2017

8

1 reference

Europe PubMed Central

30 August 2017

1475-1484

1 reference

Europe PubMed Central

30 August 2017

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

New targetable oncogenes in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU123

21 January 2018

Identifiers

10.1093/ANNONC/MDU123

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38199478&oldid=1746833922"